BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has received approval from Health Canada to start its 'Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease,' it was reported on Wednesday.
This is the first trial in Canada to assess pluripotent stem cell-derived dopaminergic neurons in subjects with Parkinson's disease. The company is enrolling 10 patients in the United States and Canada for the trial, with the Canadian trial site at University Health Network, a research and teaching hospital network located in Toronto, Ontario.
The Ph1 study's primary objective is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets
Pharming secures Japan approval for Joenja in rare immune disorder treatment
BioArctic and Eisai present new lecanemab and exidavnemab data at AD/PD 2026
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform